SGHT -
Sight Sciences, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
3.37 0.23 (6.82%) |
--- |
--- |
--- |
--- |
0.23 (6.82%) |
--- |
--- |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Earnings & Ratios
- Basic EPS:
- -0.23
- Diluted EPS:
- -0.23
- Basic P/E:
- -15.6522
- Diluted P/E:
- -15.6522
- RSI(14) 1m:
- 79.76
- VWAP:
- 3.59
- RVol:
Events
Period |
Kind |
Movement |
Occurred At |
Related News
UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery Procedures
Sep 09, 2025 15:39
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
Jul 30, 2025 11:00
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
Jul 29, 2025 11:00
Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica
Feb 10, 2025 15:00
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswire
Jul 18, 2024 20:06
Sight Sciences CFO Alison Bauerlein sells over $65k in company stock By Investing.com - Investing.com
Jul 04, 2024 00:01
Sight Sciences Announces the Release of its First Sustainability Report
Jun 10, 2024 20:05
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
May 28, 2024 20:05
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
May 28, 2024 12:30
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
May 02, 2024 22:20